Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Edward Neuberger"'
Autor:
Peter A. Kaufman, Edward Neuberger, Naomi R. M. Schwartz, Shu Wang, Yutong Liu, Ling-I Hsu, Karen Bartley, Matthew T. Blahna, Brian T. Pittner, Gabriel Wong, Carey Anders
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundTucatinib is an oral human epidermal growth factor receptor 2 (HER2)-directed therapy approved in combination with trastuzumab and capecitabine for use in patients with previously treated HER2+ metastatic breast cancer (MBC) with/without br
Externí odkaz:
https://doaj.org/article/a623ee2eb0d84c878bd93dd042adc141
Autor:
Peter A. Kaufman, Edward Neuberger, Ling-I Hsu, Naomi Schwartz, Karen Bartley, Shu Wang, Yutong Liu, Matthew T. Blahna, Brian T. Pittner, Gabriel Wong, Carey Anders
Publikováno v:
Cancer Research. 83:P4-03
Background: Tucatinib is an oral HER2-targeted therapy that was approved by the FDA in April 2020 for use in combination with trastuzumab and capecitabine for treatment of patients with previously treated HER2+ metastatic breast cancer (MBC). In the
Publikováno v:
Journal of Clinical Oncology. 41:53-53
53 Background: Current treatment options for patients with metastatic colorectal cancer (mCRC) have limited efficacy and are associated with substantial toxicity, especially for patients with mCRC refractory to standard therapies. Targeted agents may
Publikováno v:
The American journal of managed care. 28(3)
To determine whether baloxavir use is associated with lower health care resource utilization (HCRU) and costs for secondary influenza complications post treatment compared with oseltamivir.Retrospective cohort study.Patients filling a prescription fo
Publikováno v:
J Manag Care Spec Pharm
Pharmacogenetic testing can provide predictive insights about the efficacy and safety of drugs used in cancer treatment. Although many drug-gene associations have been reported in the literature, the strength of evidence supporting each association c
Publikováno v:
Open Forum Infectious Diseases
Background In the 2017-2018 influenza season, 49 million people in the US presented with influenza symptoms, resulting in substantial morbidity, mortality, and a significant humanistic and economic burden. Although there are currently four FDA-approv